High tibial osteotomy plus arthroscopic surgery for medial gonarthrosis / 中华创伤骨科杂志

Objective:To evaluate the clinical efficacy of high tibial osteotomy(HTO) plus arthroscopic surgery in the treatment of medial gonarthrosis.Methods:From January 2017 to May 2018, 40 patients were treated at Department of Joint Orthopaedics, Wujin Hospital Affiliated to Jiangsu University and at Department of Joint Orthopaedics, The First Affiliated Hospital to China Medical University for medial gonarthrosis. They were divided into 2 groups according to their different treatment methods. Group A was treated by HTO plus arthroscopic surgery; there were 20 cases, 8 males and 12 females with an age of 59.7 years ± 5.5 years. Group B was treated by only HTO; there were also 20 cases, 10 males and 10 females with an age of 58.2 years ± 4.3 years. The 2 groups were compared in terms of Hospital for Special Surgery (HSS) knee score, visual analogue scale (VAS), hip knee ankle angle (HKA), medial proximal tibia angle (MPTA) and posterior tibial slope angle (PTSA) at 6, 12 and 24 months postoperatively and at the last follow-up.Results:The 2 groups were comparable because there were no significant differences between them in the preoperative general data ( P>0.05). The HSS and VAS scores at 6 months after operation in group A (82.7±2.4 and 1.7±0.7) were significantly better than those in group B (78.4±2.6 and 2.2±0.8) ( P<0.05); the HSS score at 12 months after operation in group A (88.1±1.8) was significantly better than that in group B (82.9±1.7) ( P<0.05). There were no significant differences between the 2 group in the VAS score at 12 months after operation, or in the HSS or VAS scores at 24 months or at the last follow-up ( P>0.05). There were no significant differences either in the HKA, MPTA or PTSA scores between postoperative 6, 12, 24 months and the last follow-up ( P>0.05). Conclusion:In the treatment of medial gonarthrosis, high tibial osteotomy plus arthroscopic surgery may lead to better short-term outcomes than high tibial osteotomy alone, but the 2 methods may result in similar curative efficacy by 24 months after surgery.

Expression of human epididymis protein 4 and carbohydrate antigen 125 in endometrial carcinoma tissues / 新乡医学院学报

Objective To observe the expression of human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) in endometrial carcinoma(EC) tissues,and to explore the relationship between the expression of HE4 and CA125 and the occurrence and development of EC.Methods The EC and paracancerous tissue specimens of 35 EC patients were selected from December 2015 to December 2016 in the First People's Hospital of Yibin City.The expression of HE4 and CA125 in EC tissues and paracancerous tissues was detected by immunohistochemistry.The relationship between the expression of HE4,CA125 and the clinicopathological features of EC was analyzed;and the correlation between HE4 and CA125 was analyzed too.Results The positive expression rates of HE4 and CA125 in EC tissues were 82.9％ (29/35) and 74.3％ (26/35);they were 11.4％ (4/35) and 14.3％ (5/35) in paracancerous tissues respectively;the positive expression rates of HE4and CA125 in EC tissues were significantly higher than those in paracancerous tissues(x2 =35.831,25.533;P ＜0.05).The positive expression rates of HE4 and CA125 in stage Ⅲ and Ⅳ EC tissues were 100.0％ (20/20) and 90.0％ (18/20);they were 60.0％ (9/15) and 53.3％ (8/15) in stage Ⅰ and Ⅱ EC tissues respectively;the positive expression rates of HE4 and CA125 in stage Ⅲ and Ⅳ EC tissues were significantly higher than those in stage Ⅰ and Ⅱ EC tissues(x2 =9.655,4.266;P ＜ 0.05).The positive expression rates of HE4 and CA125 in medium and low differentiated EC tissues were 100.0％ (18/18) and 83.3％ (15/18);they were 64.7％ (11/17) and 64.7％ (11/17) in highly differentiated EC tissues respectively;the positive expression rates of HE4 and CA125 in medium and low differentiated EC tissues were significantly higher than those in highly differentiated EC tissues(x2 =7.667,4.137;P ＜0.05).The positive expression rates of HE4 and CA125 in EC tissues with myometrial invasion depth≥ 1/2 were 100.0％ (18/18) and 94.4％ (17/18);they were 64.7％ (11/17) and 52.9％(9/17) in EC tissues with myometrial invasion depth ＜ 1/2 respectively;the positive expression rates of HE4 and CA125 in EC tissues with myometrial invasion depth ≥ 1/2 were significandy higher than those in EC tissues with myometrial invasion depth ＜ 1/2(x2 =7.667,7.884;P ＜ 0.05).The positive expression rates of HE4 and CA125 in EC tissues with lymph node metastasis were 100.0％ (19/19) and 78.9％ (15/19);they were 62.5％ (10/16) and 68.8％ (11/16) in EC tissues without lymph node metastasis respectively;the positive expression rate of HE4 in EC tissues with lymph node metastasis was significantly higher than that in EC tissues without lymph node metastasis (x2 =8.599,P ＜ 0.05),but there was no significant difference in the positive expression rate of CA125 in EC tissues with lymph node metastasis and without lymph node metastasis (x2 =0.473,P ＜0.05).The expression of HE4 and CA125 in EC tissues was not related to age,tumor size and pathological type(P ＜ 0.05).The expression of HE4 in EC tissues was positively correlated with the expression of CA125 (r =0.608,P ＜0.05).Conclusion HE4 and CA125 may be involved in the development and development of EC.The expression of HE4 and CA125 is high in EC tissues,the expression level of them is closely related to clinical stage,histological differentiation and myometrial invasion depth of EC.The high expression of HE4 was also related to lymph node metastasis.

Comparison of the anti-leukemia effect and mechanism of L-asparaginase between two different strains / 中国实验血液学杂志

This study was purposed to compare the anti-leukemic effects of E.coli-L-Asp and Erwinia-L-Asp in vitro, and to investigate their mechanism. The cell apoptosis and proliferation inhibition rate were measured by CCK-8 kit, and IC50 of two drugs was calculated by using SPSS software. Pro-apoptosis effect of E.coli-L-Asp and Erwinia-L-Asp on REH and Jurkat cell lines was also determined by flow cytometry with Annexin V/PI double staining. Concentration changes of 4 amino acids (Asn, Aspa, Gln, and Glu) before and after medication were detected by using high pressure liquid chromatography (HPLC) assay. The results showed that both REH and Jurkat cell lines were sensitive to L-Asp drugs from two different strains, and E.coli-L-Asp and Erwinia-L-Asp displayed the inhibition effect on the proliferation of Jurkat and REH cell lines in dose-dependent and time-dependent manners. The inhibition cell of proliferation and cell apoptosis in Erwinia-L-Asp group were higher than those in E.coli-L-Asp group after 24 hours (P < 0.05) . However, after treatment of REN and Jurkat cells with 2 kind of L-Asp for 48 hours, the inhibition of cell proliferation and apoptosis rates were not significantly different between the 2 L-Asp drugs (P > 0.05). The Asn in medium could be depleted by two different L-Asp drugs with low concentration. Both the two L-Asp drugs had the same capability to deplete the Asn surrounding leukemia cells (P > 0.05). The Gln in medium could be depleted by two L-Asp drugs with high concentration. The hydrolysis effect of Erwinia-L-Asp on Gln was stronger than that of E.coli-L-Asp (P < 0.05). It is concluded that in a certain range of concentrations, E.coli-L-Asp and Erwinia-L-Asp exert anti-leukemia effect in dose-dependent manner. Depletion of Gln and Asn in surrounding environment and induction of cell apoptosis are two potential mechanisms, by which leukemia cells can be killed. Erwinia-L-Asp may be chosen as the first-line drug to treat childhood ALL for its fast action and stronger hydrolysis effect on Gln.

Effect of nitric oxide derived from endothelial nitric oxide synthase on tumor angiogenesis / 癌症

<p><b>BACKGROUND AND OBJECTIVE</b>Studies have shown that nitric oxide (NO) derived from endothelial nitric oxide synthase (eNOS) is expressed widely in tumor tissues and regulates tumor angiogenesis. However, the results are controversial. This study was to investigate the effect of NO on tumor angiogenesis and its mechanism.</p><p><b>METHODS</b>C57BL/6 mice inoculated with Lewis lung cancer cells were randomly divided into three groups. Mice in the NO group were inoculated with lung cancer cells transfected with eNOS gene, mice in the L-NAME group with L-NAME, an eNOS antagonist, and mice in the control group with normal saline. Plasma concentration of NO and the number of endothelial progenitor cells (EPCs) in peripheral blood were detected . Tumor vessel density, CD133+ cells, and the expression of VEGF-VEGFR in tumor tissues were also measured.</p><p><b>RESULTS</b>Four weeks after inoculation of Lewis cells, tumor volume was significantly larger in control group [ (3022 +/- 401) mm(3)] than in the L-NAME group [ (1204 +/-97) ) mm(3)] and in the eNOS group [(1824 +/- 239) mm(3)] (P<0.01). eNOS protein and NO production increased significantly in Lewis lung cancer cells transfected with eNOS gene. But the number of CD133-positive cells and vessel density in tumors were significantly lower in the eNOS group than in the control group [(48+/-19) / HPF vs. ( 103 +/- 27)/ HPF, (19+/- 7) HPF vs. (31 +/- 9) HPF, P<0.05]. The number of EPCs in peripheral blood was not statistically different between each group. The levels of NO in blood and tumor tissue significantly decreased after the treatment of L-NAME, while the tumor vessel density reduced to 12+/- 5/ HPF (P<0.01, vs. the control group; P<0.05, vs the eNOS transfected group). The number of EPCs in blood and that of CD133-positive cells in tumor tissue were significantly smaller in the L-NAME group than in the control group (P<0.05).</p><p><b>CONCLUSION</b>No derived from eNOS inhibits angiogenesis and tumor growth, which may be due to its suppression on either the mobilization or homing of EPCs via VEGF binding to VEGFR.</p>

Clinical study of endostar combined with FOLFOX as a second line chemotherapy for advanced colorectal cancer / 肿瘤研究与临床

Objective To observe prospectively and systematically the effect and safety of rhendostati injection (endostar) combined with FOLFOX as a second line chemotherapy for advanced/metastatic colorectal cancer. Methods 23 patients with histological confirmed advanced/metastatic colorectal cancer after first line chemotherapy failure were observed. The dosage of 15 mg/time of endostar solved in 500ml normal saline was slowly intravenously dropped 4 h from day 1 to day 14. Oxaliplatin 85 mg/m~2 iv 2-3 h dl, d15. CF 200 mg/m~2 iv 2 h followed by 5-Fu 400 mg iv bolus and 5-Fu 600 mg/m~2 iv 22 h dl-2, d15-16 were given, every 4 weeks as one cycle. Efficacy was evaluated after 2 cycles according to RECIST criteria. Results 23 cases had been completed totally 56 cycles. Among 23 cases, 8 cases were PR, 12 cases SD, and 3 cases PD. The objective response rate (RR) was 34.8 % (8/23), and the disease control rate (DCR) was 87.0 % (20/23). The median time to progression was 7 months. The 1-year survival rate were 50.0 %. The 2-year survival rate was 40.0 %. The occurrence rate of G3/4 toxicities was low, including neutropenia(21.7 %), anemia(4.3 %), thrombocytopenia (13.0 %). Those toxicities were mainly related with the chemotherapy agents. Meanwhile transient electrocardiogram changes mild ST-T of changes occurred in 3 cases. 2 cases were mild hypertension and were symptomatically controlled. Conclusion There are better efficacies of endostar combined with FOLFOX chemotherapy for advanced/metastatic colorectal cancer, and it is low toxic and tolerable. It is worth of further clinical observation. More experiences need to be accumulated.

Fusion expression, purification and bioassay of IFN-gamma inducible protein-10 and thioredoxin gene in E. coli / 生物医学工程学杂志

Interferon gamma-inducible protein 10, a member of the family of CXC chemokines, is secreted by interferon gamma-stimulated, monocytes, endothelial cells and keratinocytes. Interferon gamma-inducible protein 10 plays an important role in recruiting activated T cells into sites of tissue inflammation. In this experiment, PCR products of Interferon gamma-inducible protein 10 were cloned into prokaryote expression vector pET 32(a) to generate recombinant pET-IP10 with S-Tag at the N-terminus, and expressed successfully in E. coli BL21 (DE3). The total expressed products amounted to 25.3% in all bacterion proteins. pET-IP10 mainly formed inclusion body in E. coli. Soluble recombinant protein accounted for 20% among IP-10 fusion protein. The soluble recombinant proteins were purified by using S-Tag affinity chromatography effectively with purity of over 90%. The chemotaxis biological activity of purified Interferon gamma-inducible protein 10 could specifically exhibit the directional migration of stimulated T cells at concentration of 100 ng/ml. The results indicated that the strategy we used in this experiment was effective for recombinant Interferon gamma-inducible protein 10 production with biological activity.